This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Biomethodes, Hospices Civils De Lyon, Zlb Behring Gmbh. Active years: 2005-2014.
Company Filing History:
1 out of 5 
1 out of 46 
1 out of 10 Years Active: 2005-2014
Title: Claude Negrier: Innovator in Hemophilia Treatment
Introduction
Claude Negrier is a notable inventor based in Irigny, France. He has made significant contributions to the field of medicine, particularly in the treatment of hemophilia A. His work focuses on improving human FVIII variants, which are crucial for patients suffering from this condition.
Latest Patents
Negrier holds a patent for "VIII factors for the treatment of type A hemophilia." This invention relates to enhanced human FVIII variants that have at least one substitution in the A2 and/or C2 domain. The patent emphasizes the use of these variants in treating hemophilia A, especially in patients with inhibitors. He has 1 patent to his name.
Career Highlights
Throughout his career, Claude Negrier has worked with reputable organizations such as Biomethodes and Hospices Civils De Lyon. His experience in these institutions has allowed him to develop innovative solutions for hemophilia treatment.
Collaborations
Negrier has collaborated with esteemed colleagues, including Didier Saboulard and Jean-Luc Plantier. Their joint efforts have contributed to advancements in the medical field, particularly in hemophilia research.
Conclusion
Claude Negrier's work in developing improved treatments for hemophilia A showcases his dedication to medical innovation. His contributions are vital for enhancing the quality of life for patients affected by this condition.